FATAL OUTCOMES FROM DRUG INTERACTIONS: INSIGHTS FROM THE FDA ADVERSE EVENT REPORTING SYSTEM

被引：0
|
作者：
Gomez-Lumbreras, A. [1 ]
Villa, Zapata L. [2 ]
Malone, D. [1 ]
机构：
[1] Univ Utah, Dept Pharmacotherapy, Coll Pharm, Salt Lake City, UT USA
[2] Univ Georgia, Coll Pharm, Atlanta, GA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH103
引用
收藏
页码：S172 / S172
页数：1
相关论文
共 50 条
  • [41] Adverse drug reactions of intravesical instillation therapy for bladder cancer: based on FDA adverse event reporting system
    Liu, Xiang
    Wang, Zixin
    Peng, Cong
    Zhou, Jiaming
    Chen, Minggen
    Luo, Longhua
    Sun, Xiang
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [42] The FDA Drug Safety Surveillance Program: Adverse Event Reporting Trends
    Weiss-Smith, Sheila
    Deshpande, Gaurav
    Chung, Stephanie
    Gogolak, Victor
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2011, 171 (06) : 591 - 593
  • [43] Assessing Adverse Drug Reactions Reported for New Respiratory Medications in the FDA Adverse Event Reporting System Database
    Kim, Hyunwoo
    Pfeiffer, Colin M.
    Gray, Matthew P.
    Stottlemyer, Britney A.
    Boyce, Richard D.
    Kane-Gill, Sandra L.
    [J]. RESPIRATORY CARE, 2021, 66 (11) : 1739 - 1745
  • [44] Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS)
    Li, Ruibo
    Yuan, Xingyue
    Chen, Xi
    Ou, Yili
    Chen, Jin
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [45] A Review of Drug Reaction with Eosinophilia and Systemic Symptoms in the FDA Adverse Event Reporting System FAERS)
    Bluestein, Sara
    Yu, Roger
    Stone, Cosby
    Phillips, Elizabeth
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB12 - AB12
  • [46] Pediatric drug-induced anaphylaxis reports in the FDA Adverse Event Reporting System (FAERS)
    Brameli, Anna
    Yuan, Irene H.
    Phillips, Elizabeth J.
    Stone Jr, Cosby A.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2024, 12 (09):
  • [47] Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system
    Vickers-Smith, Rachel
    Sun, Jiangwen
    Charnigo, Richard J.
    Lofwall, Michelle R.
    Walsh, Sharon L.
    Havens, Jennifer R.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2020, 206
  • [48] Patient Relevant Outcomes Associated with Generic Drugs in FDA's Adverse Event Reporting System
    Marimuthu, Sathiya Priya
    Iyer, Geetha S.
    Segal, Jodi B.
    Singh, Sonal
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 421 - 422
  • [49] Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system
    Jeong, Eugene
    Nelson, Scott D.
    Su, Yu
    Malin, Bradley
    Li, Lang
    Chen, You
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [50] A Review of Dental Adverse Events Using the FDA Adverse Event Reporting System
    Altman, Keith
    Budny, Renata
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 400 - 400
12345